Trial Profile

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; AZD 8421 (Primary) ; Camizestrant (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms CYCAD-1
Sponsors AstraZeneca

18 May 2025 Planned number of patients changed from 204 to 348.
26 Mar 2025 Planned End Date changed from 18 May 2026 to 17 Jun 2026.
26 Mar 2025 Planned primary completion date changed from 18 May 2026 to 17 Jun 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com